The ability to make patient-specific products quickly fits with the needs of smaller, resource-limited developers.

FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” with biopharma leaders attending BIO in Boston.

FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA”—one that would decide on drug applications much faster, ...

Noetik will use its multimodal AI models to identify which patients will most likely benefit from Agenus’s lead ...

MICB and NOTCH4 were expressed in fibroblasts and endothelial cells, two cell types that play central roles in fibrosis and vasculopathy.

Researchers say using physically patterned surfaces applied to existing device materials would reduce barriers to commercial application.

RNA-seq and spatial transcriptomics showed immune cell subsets that drive kidney and lung complications in systemic sclerosis patients.

An independent jury of experts will evaluate entries based on scientific merit, feasibility, and potential patient impact.

Advances are occurring in spectroscopy, reducing the challenges of rapid signal saturation and the need for extensive sample prep.

By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

Chrysalis partners with life science clients, from early-stage biofirms to pharmaceutical firms, CROs, and other life science ...